Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma [0.03%]
肝细胞癌、胆管癌和混合型双源癌的免疫检查点抑制疗法
Keiko Shichiri,Kaity H Tung,Kazuaki Takabe et al.
Keiko Shichiri et al.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma that is composed of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Given its low incidence, there is no standardized treatment protocol or...
Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Small Cell Carcinoma of Ovary Patients: A Retrospective Cohort Study [0.03%]
小细胞卵巢癌患者预后预测图表的建立及验证：回顾性队列研究
Chun Mei Yan,Ya Rong Chen,Hong Fang Li et al.
Chun Mei Yan et al.
Background: This study aimed to develop functional nomograms to predict overall survival (OS) and cancer-specific survival (CSS) of small cell carcinoma of ovary (SCCO). ...
Angiogenesis Is Associated With Aggressive Biology That Counterbalances With Tumor Immunogenicity in Hepatocellular Carcinoma [0.03%]
血管生成与具有侵略性的能够抵消肝细胞癌的肿瘤免疫原性的生物学特征有关
Raj Vaghjiani,Rongrong Wu,Kaity H Tung et al.
Raj Vaghjiani et al.
Background: Hepatocellular carcinoma (HCC) is an arterialized tumor; thus, anti-angiogenesis targeted therapy is in clinical practice. Herein, we hypothesized that HCC with high angiogenesis is biologically aggressive wit...
Increased Sirtuin 6 Activity in Tumor Cells Can Prompt CD4-Positive T-Cell Differentiation Into Regulatory T Cells and Impede Immune Surveillance in the Microenvironment [0.03%]
肿瘤细胞中Sirtuin 6活性的提高可以使CD4阳性T细胞分化为调节性T细胞并妨碍微环境中的免疫监视
Nan Yang Zhang,Wen Yuan Liu,Ke Hua Fang et al.
Nan Yang Zhang et al.
Background: Sirtuin 6 (Sirt6) is expressed at increased levels in many tumors and may be involved in immunoregulation. The present study investigated how Sirt6 in tumor cells affects immune surveillance. ...
Patterns, Predictors, and Prognostic Implication of Treatment-Related Amenorrhea in Patients With Breast Cancer [0.03%]
乳腺癌患者与治疗相关的闭经的模式，预测和预后意义
Bryant Ng,Armeyra Devani Ferintasari,Susanna Hilda Hutajulu et al.
Bryant Ng et al.
Background: Treatment-related amenorrhea (TRA) is a common side effect of treatment in premenopausal patients with breast cancer, with important consequences for patient counseling and management. Its occurrence and poten...
Tumor Necrosis Factor-Alpha and Its Association With Breast Cancer: A Systematic Review [0.03%]
肿瘤坏死因子-α及其与乳腺癌的关联：系统评价
Nur Qodir,Didit Pramudhito;Legiran;Zen Hafy,Muhammad Baharul Iman et al.
Nur Qodir et al.
Background: Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine implicated in the pathogenesis and progression of various cancers, including breast cancer. Elevated TNF-α levels have been associated with ...
Should All Low-Grade Ductal Carcinoma In Situ Be Excised? Implications and Challenges of the COMET Trial [0.03%]
是否所有低级别的导管原位癌均需切除？COMET试验的启示与挑战
Hiroki Kusama,Yoshiya Horimoto,Kazuaki Takabe et al.
Hiroki Kusama et al.
CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy [0.03%]
B细胞淋巴瘤中的CD19表达及针对CD19的治疗前景中的临床考虑事项
Joseph P Marshalek,Xin Qing,Sarah Tomassetti
Joseph P Marshalek
Time to Treatment Initiation of Lung, Breast, Colorectal, and Prostate Cancers and Contributing Factors From 2015 to 2020 Utilizing Surveillance, Epidemiology, and End Results Program Database [0.03%]
2015至2020年利用监测、流行病学和最终结果程序数据库分析肺癌、乳腺癌、结直肠癌和前列腺癌的治疗开始时间及影响因素
Mariela Di Vanna,Shreya Shambhavi,Murod Khikmatov et al.
Mariela Di Vanna et al.
Background: The aim of the study was to identify the factors that cause delays in treatment initiation, such as race, gender, education, income status, and associated health comorbidities, as these can increase mortality....
Kyla Wright,Michael A Mederos,Irene R Riahi et al.
Kyla Wright et al.
Malignant biliary obstruction can, in rare cases, arise from metastases to the biliary tree from distant primary tumors. This phenomenon often poses a diagnostic challenge, as bile duct metastases may clinically and radiologically mimic pri...
Case Reports
World journal of oncology. 2025 Apr;16(2):227-234. DOI:10.14740/wjon2008 2025